register

Medical

New study confirms incubation period for coronavirus

Health Industry Hub | March 11, 2020 |

A new study published yesterday in Annals of Internal Medicine finds that the COVID-19 median incubation period is 5 days, similar to SARS, with 97.5% of patients developing symptoms within 12 days.

The authors confirm that the current period of 14 days of active monitoring is well supported by the evidence. Symptomatic disease is frequently associated with transmissibility of a pathogen. However, given recent evidence of SARS-CoV-2 transmission by mildly symptomatic and asymptomatic persons, we note that time from exposure to onset of infectiousness (latent period) may be shorter than the incubation period estimated here, with important implications for transmission dynamics.

Although the study results support current proposals for the length of quarantine or active monitoring of persons potentially exposed to SARS-CoV-2, longer monitoring periods might be justified in extreme cases. Among those who are infected and will develop symptoms, the authors expect 101 in 10 000 (99th percentile, 482) will do so after the end of a 14-day monitoring period, and the analyses do not preclude this estimate from being higher.

Although it is essential to weigh the costs of extending active monitoring or quarantine against the potential or perceived costs of failing to identify a symptomatic case, there may be high-risk scenarios (for example, a health care worker who cared for a COVID-19 patient while not wearing personal protective equipment) where it could be prudent to extend the period of active monitoring.

The outcomes of this study aim to help public health officials to set rational and evidence-based COVID-19 control policies.

Enhance corporate branding and boost your organisation’s thought leadership. How does your digital footprint measure up? Ask us how we can assist you with our digital solution.

Register FREE to receive the latest industry news, innovations and insights from Health Industry Hub; the only one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals and its key stakeholders.


News & Trends - MedTech & Diagnostics

Government commissions review as 70% of private hospitals face financial crisis

Government commissions review as 70% of private hospitals face financial crisis

Health Industry Hub | June 14, 2024 |

MedTech & Diagnostics News: Despite playing a crucial role in providing acute care and surgical services, a staggering 70% of […]

More


News & Trends - Pharmaceuticals

Pharmacy Guild echoes ACCC red flags over Chemist Warehouse-Sigma deal

Pharmacy Guild echoes ACCC red flags over Chemist Warehouse-Sigma deal

Health Industry Hub | June 14, 2024 |

Pharma News: The Pharmacy Guild of Australia has echoed the significant concerns of the Australian Competition and Consumer Commission (ACCC) […]

More


News & Trends - MedTech & Diagnostics

Competition watchdog raises concerns over cancer care provider's expansion plans

Competition watchdog raises concerns over cancer care provider’s expansion plans

Health Industry Hub | June 14, 2024 |

MedTech & Diagnostics News: A leading provider of cancer care services in Australia, faces scrutiny from the Australian Competition and […]

More


News & Trends - Biotechnology

Aussie biotech secures first local CAR T patent

Aussie biotech secures first local CAR T patent

Health Industry Hub | June 13, 2024 |

Biotech News: A Melbourne-based biotechnology company which specialises in developing immune cell therapies for cancer treatment, has been granted its […]

More


This content is copyright protected. Please subscribe to gain access.